Information Provided By:
Fly News Breaks for March 6, 2017
UTHR
Mar 6, 2017 | 05:55 EDT
Jefferies analyst Eun Yang downgraded United Therapeutics to Underperform saying her firm's physician poll indicates competitor Uptravi continues to impact the treprostinil franchise. Further, the analyst notes generic Remodulin potentially puts 35% of United Therapeutics' sales at risk. The analyst sees downside risk to consensus estimates and keeps a $116 price target for the shares.
News For UTHR From the Last 2 Days
There are no results for your query UTHR